Merck confirms $11.5bn Acceleron takeover dealAfter days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 Share XMerck confirms $11.5bn Acceleron takeover dealhttps://pharmaphorum.com/news/merck-confirms-11-5bn-acceleron-takeover-deal/
Rumour mill says Acceleron is speeding towards $11bn saleUS biopharma company Acceleron is the next company heading for a takeover by a big pharma group – Share XRumour mill says Acceleron is speeding towards $11bn salehttps://pharmaphorum.com/news/rumour-mill-says-acceleron-is-speeding-towards-11bn-sale/
EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
